Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CYP2D6 | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-06 |
mRNA | ADARB2 | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-06 |
mRNA | CAST | CTRPv2 | pan-cancer | AAC | -0.16 | 6e-06 |
mRNA | TADA1 | CTRPv2 | pan-cancer | AAC | 0.17 | 6e-06 |
mRNA | KNTC1 | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-06 |
mRNA | LIG1 | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-06 |
mRNA | TCF20 | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-06 |
mRNA | DIRAS1 | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-06 |
mRNA | PSMA7 | CTRPv2 | pan-cancer | AAC | -0.15 | 6e-06 |
mRNA | ZNF337 | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-06 |